Loading companies…
Loading companies…
United States · Biotech
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series D | $66M | abrdn — Role not disclosedBain Capital Life Sciences — Role not disclosedEurofarma Ventures — Role not disclosedForesite Capital — Role not disclosedKaitai Capital — Role not disclosedMass General Brigham Ventures — Role not disclosedNancy Chang — Role not disclosedNew Enterprise Associates (NEA) — Role not disclosedNew Leaf Venture Partners — Role not disclosedPontifax — Role not disclosedRA Capital Management — Role not disclosedRedmile Group — Role not disclosedRock Springs Capital — Role not disclosedSamsara BioCapital — Role not disclosedSanofi Ventures — Role not disclosedShang Bay — Role not disclosedSoleus Capital — Role not disclosed |